Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: Results from a randomized controlled trial

A multi-center survey of age of sexual debut and sexual behavior in Chinese women: Suggestions for optimal age of human papillomavirus vaccination in China

(2012) Fang-Hui Zhao et al.   Cancer Epidemiology

Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: A pooled analysis of 17 population-based studies

(2012) Fang-Hui Zhao et al.   INTERNATIONAL JOURNAL OF CANCER

Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine

(2011) Francis J. Dessy et al.   Human vaccines & immunotherapeutics

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

(2011) Matti Lehtinen et al.   LANCET ONCOLOGY

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

(2011) Cosette M Wheeler et al.   LANCET ONCOLOGY

Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase I trial

(2011) Feng-Cai Zhu et al.   Chinese Journal of Cancer

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials

(2010) Dominique Descamps et al.   Human vaccines & immunotherapeutics

Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication

(2010) Ni Li et al.   INTERNATIONAL JOURNAL OF CANCER

Efficacy of Human Papillomavirus Type 16/18 AS04-Adjuvanted Vaccine in Japanese Women Aged 20 to 25 Years

(2010) Ryo Konno et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18

(2009) Wen Chen et al.   CANCER CAUSES & CONTROL

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years

(2009)   LANCET

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

(2009) J Paavonen et al.   LANCET

Persistent Human Papillomavirus Infection and Cervical Neoplasia: A Systematic Review and Meta-Analysis

(2008) J. Koshiol et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis

(2008) Y P Bao et al.   INTERNATIONAL JOURNAL OF STD & AIDS

Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica

(2008) Rolando Herrero et al.   VACCINE